Balyasny Asset Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-16,595
| Closed | -$226K | – | 2114 |
|
|
2025
Q1 | $226K | Sell |
16,595
-399,479
| -96% | -$5.43M | ﹤0.01% | 1782 |
|
|
2024
Q4 | $8.48M | Buy |
416,074
+370,966
| +822% | +$7.56M | 0.01% | 715 |
|
|
2024
Q3 | $1.31M | Sell |
45,108
-75,504
| -63% | -$2.2M | ﹤0.01% | 1251 |
|
|
2024
Q2 | $2.8M | Sell |
120,612
-242,415
| -67% | -$5.63M | ﹤0.01% | 975 |
|
|
2024
Q1 | $7.45M | Buy |
363,027
+102,440
| +39% | +$2.1M | 0.01% | 767 |
|
|
2023
Q4 | $5.59M | Buy |
+260,587
| New | +$5.59M | 0.01% | 762 |
|
|
2023
Q1 | – | Sell |
-1,313
| Closed | -$36.5K | – | 2294 |
|
|
2022
Q4 | $36.5K | Buy |
+1,313
| New | +$36.5K | ﹤0.01% | 1957 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 2428 |
|
|
2022
Q1 | – | Sell |
-12,874
| Closed | -$574K | – | 2190 |
|
|
2021
Q4 | $574K | Buy |
12,874
+6,510
| +102% | +$290K | ﹤0.01% | 1369 |
|
|
2021
Q3 | $321K | Sell |
6,364
-95,570
| -94% | -$4.82M | ﹤0.01% | 1323 |
|
|
2021
Q2 | $8M | Buy |
101,934
+33,832
| +50% | +$2.65M | 0.04% | 515 |
|
|
2021
Q1 | $3.89M | Buy |
68,102
+18,028
| +36% | +$1.03M | 0.02% | 651 |
|
|
2020
Q4 | $4.19M | Sell |
50,074
-13,886
| -22% | -$1.16M | 0.02% | 593 |
|
|
2020
Q3 | $2.29M | Buy |
+63,960
| New | +$2.29M | 0.02% | 629 |
|
|
2020
Q2 | – | Sell |
-54,266
| Closed | -$950K | – | 1033 |
|
|
2020
Q1 | $950K | Buy |
+54,266
| New | +$950K | 0.01% | 654 |
|
|
2019
Q3 | – | Sell |
-120,402
| Closed | -$2.5M | – | 1122 |
|
|
2019
Q2 | $2.5M | Buy |
+120,402
| New | +$2.5M | 0.02% | 686 |
|